Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross, Rob A Cairns, Mark D Minden, Edward M Driggers, Mark A Bittinger, Hyun Gyung Jang, Masato Sasaki, Shengfang Jin, David P Schenkein, Shinsan M Su, Lenny Dang, Valeria R Fantin, Tak W Mak, Stefan Gross, Rob A Cairns, Mark D Minden, Edward M Driggers, Mark A Bittinger, Hyun Gyung Jang, Masato Sasaki, Shengfang Jin, David P Schenkein, Shinsan M Su, Lenny Dang, Valeria R Fantin, Tak W Mak
Abstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of alpha-ketoglutarate (alpha-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and alpha-KG. This prevents the oxidative decarboxylation of isocitrate to alpha-KG, and facilitates the conversion of alpha-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
Figures
References
- Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602 10.1007/s00401-008-0455-2
- Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A., et al. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30:7–11 10.1002/humu.20937
- Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744
- Ducray F., Marie Y., Sanson M. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:2248.
- Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., et al. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474 10.1007/s00401-009-0561-9
- Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., Lee J.Y., Yoo N.J., Lee S.H. 2009. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer. 125:353–355 10.1002/ijc.24379
- Latini A., Scussiato K., Rosa R.B., Leipnitz G., Llesuy S., Belló-Klein A., Dutra-Filho C.S., Wajner M. 2003a. Induction of oxidative stress by L-2-hydroxyglutaric acid in rat brain. J. Neurosci. Res. 74:103–110 10.1002/jnr.10735
- Latini A., Scussiato K., Rosa R.B., Llesuy S., Belló-Klein A., Dutra-Filho C.S., Wajner M. 2003b. D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur. J. Neurosci. 17:2017–2022 10.1046/j.1460-9568.2003.02639.x
- Lu W., Kimball E., Rabinowitz J.D. 2006. A high-performance liquid chromatography-tandem mass spectrometry method for quantitation of nitrogen-containing intracellular metabolites. J. Am. Soc. Mass Spectrom. 17:37–50 10.1016/j.jasms.2005.09.001
- Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058–1066 10.1056/NEJMoa0903840
- Miyauchi J., Kelleher C.A., Yang Y.C., Wong G.G., Clark S.C., Minden M.D., Minkin S., McCulloch E.A. 1987. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood. 70:657–663
- Nishihara K., Kanemori M., Kitagawa M., Yanagi H., Yura T. 1998. Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli. Appl. Environ. Microbiol. 64:1694–1699
- Nishihara K., Kanemori M., Yanagi H., Yura T. 2000. Overexpression of trigger factor prevents aggregation of recombinant proteins in Escherichia coli. Appl. Environ. Microbiol. 66:884–889 10.1128/AEM.66.3.884-889.2000
- Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812 10.1126/science.1164382
- Rzem R., Vincent M.F., Van Schaftingen E., Veiga-da-Cunha M. 2007. L-2-hydroxyglutaric aciduria, a defect of metabolite repair. J. Inherit. Metab. Dis. 30:681–689 10.1007/s10545-007-0487-0
- Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K., Delattre J.Y. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27:4150–4154 10.1200/JCO.2009.21.9832
- Schnittger S., Kern W., Tschulik C., Weiss T., Dicker F., Falini B., Haferlach C., Haferlach T. 2009. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 114:2220–2231 10.1182/blood-2009-03-213389
- Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T. 2009. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 100:1996–1998 10.1111/j.1349-7006.2009.01270.x
- Struys E.A. 2006. D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect. J. Inherit. Metab. Dis. 29:21–29 10.1007/s10545-006-0317-9
- Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. 2009. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174:1149–1153 10.2353/ajpath.2009.080958
- Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., Ding J. 2004. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279:33946–33957 10.1074/jbc.M404298200
- Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765–773 10.1056/NEJMoa0808710
- Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 324:261–265 10.1126/science.1170944
Source: PubMed